Nxera Pharma Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Nxera Pharma Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Nxera Pharma Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Nxera Pharma Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Nxera Pharma Co Ltd (Nxera Pharma) is a biopharmaceutical company that develops specialty medicines for unmet needs. The company pipeline products include EP4 antagonist for immuno-oncology disorders; GPR52 agonist which targets schizophrenia; EP4 agonist for the treatment of inflammatory bowel disease; Muscarinic M1-preferring agonist which treats neurology disorders; GPR35 agonist for inflammatory bowel disease and GI disorders; GLP-1 agonist, GIP antagonist, and Amylin agonist which targets obesity-related diseases. It markets its products under the PIVLAZ, and QUVIVIQ brand names. The company operates in the UK and Switzerland. Nxera Pharma is headquartered in Minato-ku, Tokyo, Japan.
Headquarters
Japan
Address
7f, Midtown East, 9-7-2, Akasaka, Minato-Ku, Tokyo, 107-0052
Website
www.nxera.life
Telephone
81 3 59625718
No of Employees
382
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4565 (TYO)
Revenue (2024)
$190.3M
2.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-159%
(2024 vs 2023)
Market Cap*
$566.9M
Net Profit Margin (2024)
XYZ
-152.2%
(2024 vs 2023)
* As of and is in US$
Nxera Pharma Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| PIVLAZ (clazosentan): | PIVLAZ |
| Cerebral Vasospasm | QUVIVIQ |
| Vasospasm-Related Cerebral Infarction | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In January, Nxera Pharma UK Ltd entered into a license agreement with Santhera Pharmaceuticals for the development and commercialization of AGAMREE (vamorolone) in Japan, South Korea, Australia, and New Zealand. |
| 2025 | Others | In April, the company's partner, Neurocrine Biosciences, initiated a Phase 3 trial for NBI-1117568, an investigational oral muscarinic M4 receptor agonist, as a potential treatment for schizophrenia. |
| 2025 | Contracts/Agreements | In February, the company signed an assignment agreement with Viatris and Idorsia Pharmaceuticals to promote the development and commercialization of cenerimod. |
Competitor Comparison
| Key Parameters | Nxera Pharma Co Ltd | ASKA Pharmaceutical Holdings Co Ltd | Fuso Pharmaceutical Industries Ltd | Torii Pharmaceutical Co Ltd | Daito Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Minato-Ku | Minato-Ku | Osaka | Chuo-ku | Toyama |
| State/Province | Tokyo | Tokyo | Osaka | Tokyo | Toyama |
| No. of Employees | 382 | 1,632 | 1,340 | 592 | 1,073 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chris Cargill | President; Chairman; Chief Executive Officer | Executive Board | 2022 | - |
| Hironoshin Nomura | Chief Financial Officer | Senior Management | 2022 | - |
| Toshi Maeda | President - Nxera Pharma Japan; Chief Operating Officer | Senior Management | - | - |
| Kieran Johnson | Chief Accounting Officer | Senior Management | 2022 | - |
| Mariko Nakafuji | Chief Legal Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer